|
 |
Chiltern |
 |
|
|
Established in 1982, Chiltern is a leading global contract research
organization with extensive experience in running and staffing international
Phase I to Phase IV clinical trials across a broad therapeutic range for a wide
variety of clients. Chiltern provides services including Early Phase, Global
Clinical Development, Late Phase, Biometrics, Regulatory and Medical Affairs,
and Resourcing Solutions. Chiltern employs more than 1,200 people working out
of 23 offices across the United States,
Europe, Latin America and India.
Services
• Early Phase
• Global Clinical Development
• Late Phase
• Biometrics
• Medical and Regulatory Affairs
• Resourcing Solutions
Therapeutic areas of experience
• Cardiovascular
• CNS
• Infectious Diseases
• Oncology
• Ophthalmology
• Pediatrics
Chiltern
International Ltd.
Stuart McGuire
Executive Director, Strategic Development, Europe
+44 (0) 1753 512 000
Chiltern International Inc.
Mac McElroy
Executive Director, Strategic Development, Americas
+1 (423) 968 9533
|
|
|
|
|
 |
UK:+44(0)1753 512 000; US:+1 (423) 968 9533 |
 |
info@chiltern.com |
 |
www.chiltern.com |
 |
UK: 171 Bath Road, Slough, Berkshire, SL1 4AA. US: 1241 Volunteer Parkway, Suite 950, Bristol, TN 37620. |
|
| |
|
|
 |
|
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
|
